Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1161-1170 of 1,467) with videos related to

Pageof 147
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2007
TNF-induced structural joint damage is mediated by IL-1Jochen Zwerina, Kurt Redlich, Karin Polzer, et al.
Lancet (London, England)|June 21, 2017
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialRoy Fleischmann, Eduardo Mysler, Stephen Hall, et al.
RMD Open|January 30, 2026
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trialJosef S Smolen, Ted R Mikuls, James Galloway, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Arthritis Research & Therapy|January 19, 2015
CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritisOlga N Karpus, Hans P Kiener, Birgit Niederreiter, et al.
Journal of the American Chemical Society|January 20, 2018
Chemical Design of Both a Glutathione-Sensitive Dimeric Drug Guest and a Glucose-Derived Nanocarrier Host to Achieve Enhanced Osteosarcoma Lung Metastatic Anticancer SelectivityLu Su, Richen Li, Sarosh Khan, et al.
Rheumatology (Oxford, England)|February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritisMark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Clinical and Experimental Rheumatology|February 18, 2014
The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational studyR Westhovens, R F van Vollenhoven, D T Boumpas, et al.
Annals of the Rheumatic Diseases|October 5, 2018
Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trialMargreet Kloppenburg, Roberta Ramonda, Klaus Bobacz, et al.
Rheumatology (Oxford, England)|September 2, 2024
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritisJosef S Smolen, Peter C Taylor, Yoshiya Tanaka, et al.
Pageof 147

Showing results (1161-1170 of 1,467) with videos related to

Sort By:
Pageof 147
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2007
TNF-induced structural joint damage is mediated by IL-1Jochen Zwerina, Kurt Redlich, Karin Polzer, et al.
Lancet (London, England)|June 21, 2017
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialRoy Fleischmann, Eduardo Mysler, Stephen Hall, et al.
RMD Open|January 30, 2026
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trialJosef S Smolen, Ted R Mikuls, James Galloway, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Arthritis Research & Therapy|January 19, 2015
CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritisOlga N Karpus, Hans P Kiener, Birgit Niederreiter, et al.
Journal of the American Chemical Society|January 20, 2018
Chemical Design of Both a Glutathione-Sensitive Dimeric Drug Guest and a Glucose-Derived Nanocarrier Host to Achieve Enhanced Osteosarcoma Lung Metastatic Anticancer SelectivityLu Su, Richen Li, Sarosh Khan, et al.
Rheumatology (Oxford, England)|February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritisMark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Clinical and Experimental Rheumatology|February 18, 2014
The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational studyR Westhovens, R F van Vollenhoven, D T Boumpas, et al.
Annals of the Rheumatic Diseases|October 5, 2018
Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trialMargreet Kloppenburg, Roberta Ramonda, Klaus Bobacz, et al.
Rheumatology (Oxford, England)|September 2, 2024
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritisJosef S Smolen, Peter C Taylor, Yoshiya Tanaka, et al.
Pageof 147